Xu-Rui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xu-Rui Liu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Fei Liu
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications - Tian-Wu Chen
Department of Radiology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications - Xiao-Yu Liu
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
2 shared publications - Zi-Wei Li
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
2 shared publications - Bin Zhang
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
1 shared publication - Bing Kang
Department of Clinical Nutrition, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
1 shared publication
Latest Publications
- 26 October 2026
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 22
Multiple Atypical Focal Nodular Hyperplasia of the Liver on MRI: A Case Report
Introduction/Background: Focal nodular hyperplasia of the liver is a common benign liver lesion. Up to now, only a few studies have discussed the Magnetic Resonance Imaging (MRI) findings of atypical focal nodular hyperplasia. In this paper, we report a case of multifocal atypical focal nodular hyperplasia of the liver, as demonstrated by ultrasound, magnetic resonance imaging examinations (including gadoxetic acid disodium-enhanced hepatobiliary phase imaging), and histopathological examination. This report demonstrated an uncommon multifocal atypical FNH in a male patient. Case Presentation: A 48-year-old male with chronic hepatitis C was admitted following the detection of multiple slightly hypoechoic hepatic nodules on an abdominal ultrasound examination. Contrast-enhanced magnetic resonance imaging showed four liver nodules that demonstrated mild, heterogeneous enhancement in the arterial phase, progressive enhancement in the transitional phase, and rim-like hyperintensity in the hepatobiliary phase. Due to the diagnostic uncertainty, laparoscopic partial hepatectomy was performed. Postoperative pathology confirmed the diagnosis of focal nodular hyperplasia (with a “map-like” positive pattern for glutamine synthetase). Conclusion: This case represents an uncommon presentation of multiple atypical focal nodular hyperplasias in a male patient. In the patient with chronic liver disease, mild heterogeneous arterial enhancement, progressive later-phase enhancement, and peripheral ring-like hepatobiliary-phase hyperintensity prompt consideration of atypical FNH/FNH-like lesions in the differential diagnosis.
- 26 October 2026
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 22
Multiple Atypical Focal Nodular Hyperplasia of the Liver on MRI: A Case Report
Introduction/Background: Focal nodular hyperplasia of the liver is a common benign liver lesion. Up to now, only a few studies have discussed the Magnetic Resonance Imaging (MRI) findings of atypical focal nodular hyperplasia. In this paper, we report a case of multifocal atypical focal nodular hyperplasia of the liver, as demonstrated by ultrasound, magnetic resonance imaging examinations (including gadoxetic acid disodium-enhanced hepatobiliary phase imaging), and histopathological examination. This report demonstrated an uncommon multifocal atypical FNH in a male patient. Case Presentation: A 48-year-old male with chronic hepatitis C was admitted following the detection of multiple slightly hypoechoic hepatic nodules on an abdominal ultrasound examination. Contrast-enhanced magnetic resonance imaging showed four liver nodules that demonstrated mild, heterogeneous enhancement in the arterial phase, progressive enhancement in the transitional phase, and rim-like hyperintensity in the hepatobiliary phase. Due to the diagnostic uncertainty, laparoscopic partial hepatectomy was performed. Postoperative pathology confirmed the diagnosis of focal nodular hyperplasia (with a “map-like” positive pattern for glutamine synthetase). Conclusion: This case represents an uncommon presentation of multiple atypical focal nodular hyperplasias in a male patient. In the patient with chronic liver disease, mild heterogeneous arterial enhancement, progressive later-phase enhancement, and peripheral ring-like hepatobiliary-phase hyperintensity prompt consideration of atypical FNH/FNH-like lesions in the differential diagnosis.
- 30 April 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 201, 112898
Tumor subregion-based CT habitat radiomics to improve prediction of nodal disease in esophageal squamous cell carcinoma
- 30 April 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 201, 112898
Tumor subregion-based CT habitat radiomics to improve prediction of nodal disease in esophageal squamous cell carcinoma
- Open Access
- 9 April 2025
- Published by Spandidos Publications in Oncology Letters
- Vol. 29 (6) , 1-8
Effect of laxative use and laxative type on colorectal cancer risk: A pooling up analysis and evidence synthesis
Colorectal cancer (CRC) is the third most common cancer worldwide and there is a controversy regarding the influence of laxative use on the incidence of CRC. Therefore, the present study aimed to investigate the effects of laxative use and different subtypes of laxatives on the incidence of CRC. To this aim, a comprehensive search of three databases (PubMed, Embase and the Cochrane Library) was conducted on April 12, 2022, using key words that included ‘laxative’ and ‘CRC’, which initially retrieved 305 records. Ultimately, 12 studies involving 415,313 patients met all eligibility criteria and were included in a meta‑analysis. Subsequently, patients were categorized into the laxative use and non‑laxative use groups. Stata 16.0 software was used for all data analyses. The results indicated that laxative use was not significantly associated with CRC risk [odds ratio (OR), 0.95; 95% confidence interval (CI), 0.75‑1.20; P=0.65; I2=94.63%]. In the subgroup analyses, the effects of different laxative types were further examined. Notably, all types of laxatives except for fiber laxatives showed no significant influence on CRC risk (P>0.1). By contrast, fiber laxatives were associated with a reduced risk of CRC (OR, 0.74; 95% CI, 0.59‑0.93; P=0.01; I2=32.15%), suggesting a potential protective effect of this medication. In conclusion, the findings of the present study suggest that the use of laxatives does not increase the risk of CRC. Moreover, the use of fiber laxatives may have a protective effect by reducing CRC incidence.
- 9 April 2025
- Published by Spandidos Publications in Oncology Letters
- Vol. 29 (6) , 1-8
Open AccessEffect of laxative use and laxative type on colorectal cancer risk: A pooling up analysis and evidence synthesis
Colorectal cancer (CRC) is the third most common cancer worldwide and there is a controversy regarding the influence of laxative use on the incidence of CRC. Therefore, the present study aimed to investigate the effects of laxative use and different subtypes of laxatives on the incidence of CRC. To this aim, a comprehensive search of three databases (PubMed, Embase and the Cochrane Library) was conducted on April 12, 2022, using key words that included ‘laxative’ and ‘CRC’, which initially retrieved 305 records. Ultimately, 12 studies involving 415,313 patients met all eligibility criteria and were included in a meta‑analysis. Subsequently, patients were categorized into the laxative use and non‑laxative use groups. Stata 16.0 software was used for all data analyses. The results indicated that laxative use was not significantly associated with CRC risk [odds ratio (OR), 0.95; 95% confidence interval (CI), 0.75‑1.20; P=0.65; I2=94.63%]. In the subgroup analyses, the effects of different laxative types were further examined. Notably, all types of laxatives except for fiber laxatives showed no significant influence on CRC risk (P>0.1). By contrast, fiber laxatives were associated with a reduced risk of CRC (OR, 0.74; 95% CI, 0.59‑0.93; P=0.01; I2=32.15%), suggesting a potential protective effect of this medication. In conclusion, the findings of the present study suggest that the use of laxatives does not increase the risk of CRC. Moreover, the use of fiber laxatives may have a protective effect by reducing CRC incidence.
- Open Access
- 5 October 2023
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 18 (1) , 54
The Effect of Liver Cirrhosis on Patients Undergoing Cardiac Surgery
The aim of this study was to investigate the impact of liver cirrhosis (LC) on postoperative complications and long-term outcomes in patients who underwent cardiac surgery. Three databases, including PubMed, Embase, and the Cochrane Library, were searched on July 24, 2022. A total of 1,535,129 patients were enrolled in the seven included studies for analysis. According to our analysis, LC was a risk factor for postoperative overall complications (OR = 1.48, 95% CI = 1.21 to 1.81, I2 = 90.35%, P = 0.00 < 0.1). For various complications, more patients developed pulmonary (OR = 1.86, 95% CI = 1.21 to 2.87, I2 = 90.79%, P = 0.00 < 0.1), gastrointestinal (OR = 2.03, 95% CI = 1.32 to 3.11, I2 = 0.00%, P = 0.00 < 0.05), renal (OR = 2.20, 95% CI = 1.41 to 3.45, I2 = 91.60%, P = 0.00 < 0.1), neurological (OR = 1.14, 95% CI = 1.03 to 1.26, I2 = 7.35%, P = 0.01 < 0.05), and infectious (OR = 2.02, 95% CI = 1.17 to 3.50, I2 = 92.37%, P = 0.01 < 0.1) complications after surgery in the LC group. As for cardiovascular (OR = 1.07, 95% CI = 0.85 to 1.35, I2 = 75.23%, P = 0.58 > 0.1) complications, there was no statistical significance between the 2 groups. As for long-term outcomes, we found that in-hospital death (OR = 2.53, 95% CI = 1.86 to 3.20, I2 = 44.58%, P = 0.00 < 0.05) and death (OR = 3.31, 95% CI = 1.54 to 5.07, I2 = 93.81%, P = 0.00 < 0.1) in the LC group were higher than the non-LC group. LC was a risk factor for cardiac surgery. Patients with LC who would undergo cardiac surgery should be fully assessed for the risks of cardiac surgery. Similarly, the surgeon should assess the patient’s liver function before surgery.
- 5 October 2023
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 18 (1) , 54
Open AccessThe Effect of Liver Cirrhosis on Patients Undergoing Cardiac Surgery
The aim of this study was to investigate the impact of liver cirrhosis (LC) on postoperative complications and long-term outcomes in patients who underwent cardiac surgery. Three databases, including PubMed, Embase, and the Cochrane Library, were searched on July 24, 2022. A total of 1,535,129 patients were enrolled in the seven included studies for analysis. According to our analysis, LC was a risk factor for postoperative overall complications (OR = 1.48, 95% CI = 1.21 to 1.81, I2 = 90.35%, P = 0.00 < 0.1). For various complications, more patients developed pulmonary (OR = 1.86, 95% CI = 1.21 to 2.87, I2 = 90.79%, P = 0.00 < 0.1), gastrointestinal (OR = 2.03, 95% CI = 1.32 to 3.11, I2 = 0.00%, P = 0.00 < 0.05), renal (OR = 2.20, 95% CI = 1.41 to 3.45, I2 = 91.60%, P = 0.00 < 0.1), neurological (OR = 1.14, 95% CI = 1.03 to 1.26, I2 = 7.35%, P = 0.01 < 0.05), and infectious (OR = 2.02, 95% CI = 1.17 to 3.50, I2 = 92.37%, P = 0.01 < 0.1) complications after surgery in the LC group. As for cardiovascular (OR = 1.07, 95% CI = 0.85 to 1.35, I2 = 75.23%, P = 0.58 > 0.1) complications, there was no statistical significance between the 2 groups. As for long-term outcomes, we found that in-hospital death (OR = 2.53, 95% CI = 1.86 to 3.20, I2 = 44.58%, P = 0.00 < 0.05) and death (OR = 3.31, 95% CI = 1.54 to 5.07, I2 = 93.81%, P = 0.00 < 0.1) in the LC group were higher than the non-LC group. LC was a risk factor for cardiac surgery. Patients with LC who would undergo cardiac surgery should be fully assessed for the risks of cardiac surgery. Similarly, the surgeon should assess the patient’s liver function before surgery.
- Open Access
- 27 February 2023
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2023, 1-9
The Impact of Serum Parameters Associated with Kidney Function on the Short-Term Outcomes and Prognosis of Colorectal Cancer Patients Undergoing Radical Surgery
Purpose. The current study was designed to investigate the impact of blood urea nitrogen (BUN), serum uric acid (UA), and cystatin (CysC) on the short-term outcomes and prognosis of colorectal cancer (CRC) patients undergoing radical surgery. Methods. CRC patients who underwent radical resection were included from Jan 2011 to Jan 2020 in a single clinical centre. The short-term outcomes, overall survival (OS), and disease-free survival (DFS) were compared in different groups. A Cox regression analysis was conducted to identify independent risk factors for OS and DFS. Results. A total of 2047 CRC patients who underwent radical resection were included in the current study. Patients in the abnormal BUN group had a longer hospital stay ( ) and more overall complications ( ) than that of the normal BUN group. The abnormal CysC group had longer hospital stay ( ), more overall complications ( ), and more major complications ( ) than the normal CysC group. Abnormal CysC was associated with worse OS and DFS for CRC patients in tumor stage I ( ). In Cox regression analysis, age ( , HR = 1.041, 95% CI = 1.029–1.053), tumor stage ( , HR = 2.134, 95% CI = 1.828–2.491), and overall complications ( , HR = 1.499, 95% CI = 1.166–1.928) were independent risk factors for OS. Similarly, age ( , HR = 1.026, 95% CI = 1.016–1.037), tumor stage ( , HR = 2.053, 95% CI = 1.788–2.357), and overall complications ( , HR = 1.440, 95% CI = 1.144–1.814) were independent risk factors for DFS. Conclusion. In conclusion, abnormal CysC was significantly associated with worse OS and DFS at TNM stage I, and abnormal CysC and BUN were related to more postoperative complications. However, preoperative BUN and UA in the serum might not affect OS and DFS for CRC patients who underwent radical resection.
- 27 February 2023
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2023, 1-9
Open AccessThe Impact of Serum Parameters Associated with Kidney Function on the Short-Term Outcomes and Prognosis of Colorectal Cancer Patients Undergoing Radical Surgery
Purpose. The current study was designed to investigate the impact of blood urea nitrogen (BUN), serum uric acid (UA), and cystatin (CysC) on the short-term outcomes and prognosis of colorectal cancer (CRC) patients undergoing radical surgery. Methods. CRC patients who underwent radical resection were included from Jan 2011 to Jan 2020 in a single clinical centre. The short-term outcomes, overall survival (OS), and disease-free survival (DFS) were compared in different groups. A Cox regression analysis was conducted to identify independent risk factors for OS and DFS. Results. A total of 2047 CRC patients who underwent radical resection were included in the current study. Patients in the abnormal BUN group had a longer hospital stay ( ) and more overall complications ( ) than that of the normal BUN group. The abnormal CysC group had longer hospital stay ( ), more overall complications ( ), and more major complications ( ) than the normal CysC group. Abnormal CysC was associated with worse OS and DFS for CRC patients in tumor stage I ( ). In Cox regression analysis, age ( , HR = 1.041, 95% CI = 1.029–1.053), tumor stage ( , HR = 2.134, 95% CI = 1.828–2.491), and overall complications ( , HR = 1.499, 95% CI = 1.166–1.928) were independent risk factors for OS. Similarly, age ( , HR = 1.026, 95% CI = 1.016–1.037), tumor stage ( , HR = 2.053, 95% CI = 1.788–2.357), and overall complications ( , HR = 1.440, 95% CI = 1.144–1.814) were independent risk factors for DFS. Conclusion. In conclusion, abnormal CysC was significantly associated with worse OS and DFS at TNM stage I, and abnormal CysC and BUN were related to more postoperative complications. However, preoperative BUN and UA in the serum might not affect OS and DFS for CRC patients who underwent radical resection.